Vivos Therapeutics (VVOS) Return on Equity (2020 - 2025)
Vivos Therapeutics (VVOS) has disclosed Return on Equity for 6 consecutive years, with 4.81% as the latest value for Q3 2025.
- On a quarterly basis, Return on Equity fell 301.0% to 4.81% in Q3 2025 year-over-year; TTM through Sep 2025 was 4.81%, a 301.0% decrease, with the full-year FY2024 number at 2.66%, up 257.0% from a year prior.
- Return on Equity was 4.81% for Q3 2025 at Vivos Therapeutics, down from 3.19% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 7.93% in Q3 2023 to a low of 59.63% in Q4 2023.
- A 5-year average of 5.53% and a median of 1.4% in 2022 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: crashed -5965bps in 2023, then soared 5821bps in 2024.
- Vivos Therapeutics' Return on Equity stood at 0.7% in 2021, then surged by 102bps to 0.01% in 2022, then plummeted by -437086bps to 59.63% in 2023, then soared by 98bps to 1.43% in 2024, then plummeted by -237bps to 4.81% in 2025.
- Per Business Quant, the three most recent readings for VVOS's Return on Equity are 4.81% (Q3 2025), 3.19% (Q2 2025), and 1.82% (Q1 2025).